Quinoline 3-amino chroman derivatives

Details Quinoline 3-amino chroman derivatives Quinoline 3-amino chroman derivatives

2007-06-05

2007-06-05

Desai, Rita (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S089000, C514S291000

Reexamination Certificate

active

10835128

ABSTRACT:
Quinoline 3-amino chroman derivatives and compositions containing such compounds are disclosed. Methods for using the quinoline 3-amino chroman derivatives and compositions containing such compounds in the treatment of serotonin disorders are disclosed. Also disclosed are processes for preparing quinoline 3-amino chroman derivatives.

REFERENCES:
patent: 5750724 (1998-05-01), Kang et al.
patent: 6121307 (2000-09-01), Mewshaw et al.
patent: 91/11435 (1991-08-01), None
patent: 91/13872 (1991-09-01), None
patent: 94/21608 (1994-09-01), None
patent: WO 97/17343 AA1 (1997-05-01), None
patent: 02/066475 (2002-08-01), None
patent: WO 03/010169 (2003-02-01), None
patent: WO 2004/058746 (2004-07-01), None
Perez, V., et al., “Randomised double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment,”The Lancet, 1997, 349: 1594-1597.
Feiger, A., “A Double-Blind Comparison of Gepirone Extended Release, Imipramine, and Placebo in the Treatment of Outpatient Major Depression,”Psychopharmacol. Bull., 1996, 32(4): 659-665.
Wilcox, C. et al., “A Double-Blind Trial of Low- and High-Dose Ranges of Gepirone-ER Compared With Placebo in the Treatment of Depressed Outpatients,”Psychopharmacol. Bull., 1996, 32(3): 335-342.
Grof, P. et al., “An open study of oral flesinoxan, a 5-HT1Areceptor agonist, in treatment-resistant depression,”International Clinical Psychopharmacology, 1993, 8: 167-172.
Dimitriou, E. et al., “Buspirone Augmentation of Antidepressant Therapy,”J. Clinical Psychopharmacol., 1998, 18(6): 465-469.
Remingtons Pharmaceutical Sciences, 17th edition, ed. Alfonoso R. Gennaro, Mack Publishing Company, Easton, PA (1985).
Bundgaard, (ed.),Design of Prodrugs, Elsevier (1985).
Higuchi and Stella (eds.)Prodrugs as Novel Drug Delivery Systems, American Chemical Society (1975).
Widder, et al. (ed.),Methods in Enzymology, vol. 4, Academic Press (1985).
Krogsgaard-Larsen, et al. (ed.), “Design and Application of Prodrugs”,Textbook of Drug Design and Development, Chapter 5, 113-191 (1991).
Bundgaard, J. et al., “Glycolamide Esters as Biolabile Prodrugs of Carboxylic Acid Agents: Synthesis, Stability, Bioconversion, and Physicochemical Properties,”Pharmaceutical Sciences, 77(4):285-298 (Apr. 1988).
Bundgaard, H. et al., “Prodrugs as a means to improve the delivery of peptide drugs,”Advanced Drug Delivery Reviews, Elsevier Science Publishers, 8:1-38 (1992).
Cheetham, S. C. et al., “[3H]Paroxetine Binding in Rat Frontal Cortex Strongly Correlates With [3H]5-HT Uptake: Effect of Administration of Various Antidepressant Treatments,”Neuropharmacol., 1993, 32: 737-743.
Hall, M. D. et al. “[3H]8-Hydroxy-2-(Di-n-Propylamino)Tetralin Binding to Pre- and Postsynaptic 5-Hydroxytryptamine Sites in Various Regions of the Rat Brain,”J. Neurochem., 1985, 44(6): 1685-1696.
Lazareno, S. and Birdsall, N.J.M., “Pharmacological characterization of acetylcholine-stimulated [35S]-GTPγS binding mediated by human muscarinic m1—m4 receptors: antagonist studies,”Br. J. Pharmacol., 1993, 109:1120-1127.

Affiliated with

Also associated with

Rating

Quinoline 3-amino chroman derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Quinoline 3-amino chroman derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Quinoline 3-amino chroman derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3858385